bunyavirus
signific
human
pathogen
caus
diseas
rang
hemorrhag
fever
enceph
among
virus
la
cross
viru
lacv
member
california
serogroup
circul
eastern
midwestern
unit
state
lacv
infect
often
asymptomat
dozen
case
enceph
report
yearli
unfortun
antivir
approv
treat
lacv
infect
develop
method
rapidli
test
potenti
antivir
lacv
infect
screen
identifi
sever
potenti
antivir
molecul
includ
known
antivir
addit
identifi
mani
novel
antivir
exhibit
antivir
activ
without
affect
cellular
viabil
valinomycin
potassium
ionophor
among
top
target
found
valinomycin
exhibit
potent
antilacv
activ
multipl
cell
type
dosedepend
manner
valinomycin
affect
particl
stabil
infect
suggest
may
preclud
viru
replic
alter
cellular
potassium
ion
known
determin
lacv
entri
extend
result
ionophor
found
antivir
activ
valinomycin
extend
viral
famili
includ
bunyavirus
rift
valley
fever
viru
keyston
viru
enterovirus
coxsackieviru
rhinoviru
flavirivus
zika
coronavirus
merscov
viral
infect
observ
signific
reduct
viru
titer
valinomycintr
cell
sum
demonstr
import
potassium
ion
viru
infect
suggest
potenti
therapeut
target
disrupt
viru
replic
import
antivir
approv
treatment
bunyaviru
infect
abil
rapidli
screen
compound
identifi
novel
antivir
one
mean
acceler
drug
discoveri
virus
approv
treatment
use
approach
screen
hundr
compound
la
cross
viru
emerg
bunyaviru
caus
signific
diseas
includ
enceph
identifi
sever
known
previous
unidentifi
antivir
focus
potassium
ionophor
valinomycin
due
promis
vitro
antivir
activ
demonstr
valinomycin
well
select
ionophor
exhibit
activ
la
cross
viru
well
sever
distantli
relat
bunyavirus
final
observ
valinomycin
activ
wide
array
human
viral
pathogen
suggest
disrupt
potassium
ion
homeostasi
valinomycin
may
potent
host
pathway
target
quell
viru
infect
daptomycin
among
other
close
relat
lacv
rvfv
screen
highlight
azauridin
mitoxatron
abil
rapidli
screen
molecul
highlight
opportun
identifi
uniqu
virusspecif
broadspectrum
antivir
report
highlight
viral
process
sever
benefit
includ
potenti
broadspectrum
activ
heighten
requir
antivir
resist
beyond
minor
mutat
viru
addit
numer
approv
avail
drug
alreadi
avail
repurpos
antivir
signific
work
remain
done
identifi
verifi
antivir
rapidli
screen
compound
provid
insight
use
nih
development
therapeut
program
dtp
obtain
screen
compound
activ
lacv
identifi
sever
known
antivir
includ
deoxyuridin
quinonon
importantli
also
identifi
varieti
novel
class
antivir
includ
metal
ion
chelat
valinomycin
top
hit
screen
function
transport
potassium
ion
electrochem
gradient
investig
antivir
activ
valinomycin
observ
valinomycin
exhibit
antivir
activ
sever
cellular
system
dosedepend
manner
independ
treatment
time
also
found
valinomycin
directli
inactiv
viral
particl
highlight
cellular
role
potassium
ion
viru
infect
expand
result
addit
ionophor
observ
effect
block
lacv
replic
final
determin
valinomycin
broadli
antivir
reduc
replic
sever
virus
divers
famili
includ
flavivirus
enterovirus
togeth
data
highlight
util
rapid
screen
antivir
molecul
well
crucial
role
potassium
ion
lacv
infect
develop
rapid
screen
nih
dtp
compound
activ
lacv
develop
simpl
rapid
assay
measur
antivir
activ
cell
figur
plate
cell
confluenc
plate
ad
drug
nih
nci
importantli
cytotox
molecul
would
stain
crystal
violet
thu
stain
cell
indic
antivir
molecul
cytotox
crystal
violet
stain
subsequ
resuspend
acet
acid
absorb
read
nm
control
interpl
variabl
plate
contain
untreat
infect
low
surviv
untreat
uninfect
high
surviv
ribavirintr
control
high
surviv
absorb
drugtreat
infect
well
figur
compar
untreat
uninfect
control
divid
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
absorb
valu
figur
ratio
highlight
sever
candid
antivir
includ
lagistas
lapachol
superacyl
valinomycin
interestingli
identifi
sever
known
antivir
screen
includ
deoxyuridin
nelarabin
summar
tabl
thu
assay
identifi
molecul
novel
activ
lacv
includ
recogn
antivir
valinomycin
restrict
lacv
replic
focus
valinomycin
molecul
promin
hit
screen
known
mechan
relev
lacv
infect
previous
describ
antivir
activ
lacv
initi
consider
antivir
activ
perform
secondari
screen
cell
cell
seed
confluenc
treat
increas
dose
valinomycin
infect
moi
cell
fix
stain
crystal
violet
stain
quantifi
absorb
read
observ
valinomycin
exhibit
antivir
activ
dose
crystal
violet
stain
stronger
suggest
surviv
cell
figur
dose
high
affect
crystal
violet
stain
suggest
cellular
viabil
compromis
confirm
phenotyp
titer
treat
cell
increas
dose
valinomycin
prior
infect
moi
measur
titer
plaqu
assay
hpi
observ
viral
titer
significantli
decreas
compar
untreat
control
figur
dot
line
concentr
fact
viral
titer
reduc
calcul
valu
confirm
cellular
viabil
compromis
use
fluoresc
assay
measur
cellular
atp
content
treatment
increas
dose
valinomycin
observ
cellular
toxic
dose
figur
valu
though
toxic
observ
either
cellular
morpholog
fluoresc
atp
assay
confirm
valinomycin
antivir
activ
measur
cellassoci
viral
genom
cell
treat
infect
cellassoci
rna
collect
hpi
rna
purifi
revers
transcrib
analyz
via
qpcr
small
medium
larg
genom
segment
normal
cellular
parallel
titer
data
valinomycin
treatment
reduc
viral
genom
content
dosedepend
manner
figur
viral
genom
content
reduc
upward
valinomycin
treatment
extend
result
cell
type
treat
infect
cell
determin
viral
titer
plaqu
assay
hpi
observ
signific
reduct
viral
titer
multipl
cell
type
reduc
viral
titer
cellassoci
viral
genom
depend
manner
valinomycin
antivir
multipl
round
infect
initi
assay
perform
low
moi
viral
titer
measur
hpi
determin
valinomycin
antivir
sever
round
replic
treat
cell
valinomycin
two
hour
prior
infect
moi
subsequ
collect
sampl
titer
everi
total
found
lacv
titer
significantli
reduc
time
hpi
figur
fact
viru
fail
replic
input
viru
titer
confirm
valinomycin
reduc
viru
replic
measur
viral
rna
genom
end
treat
cell
increas
dose
valinomycin
infect
lacv
collect
cellassoci
rna
trizol
hpi
purifi
reversetranscrib
perform
qpcr
use
primer
specif
small
medium
larg
genom
segment
observ
treatment
valinomycin
significantli
reduc
number
viral
genom
treatment
individu
genom
segment
affect
anoth
figur
togeth
data
suggest
valinomycin
block
viru
replic
reduc
viral
rna
accumul
valinomycin
reduc
viral
particl
infect
observ
signific
reduct
lacv
titer
valinomycin
treatment
hypothes
valinomycin
might
directli
affect
cellular
process
reduc
viru
infect
nonetheless
valinomycin
cyclic
peptid
could
potenti
directli
inactiv
viral
particl
seen
previous
test
whether
valinomycin
directli
reduc
viru
infect
directli
incub
lacv
valinomycin
directli
titer
surviv
viru
regular
interv
found
valinomycin
significantli
alter
viral
titer
time
examin
figur
suggest
valinomycin
directli
inactiv
viral
particl
examin
capac
valinomycin
inactiv
particl
incub
increas
dose
valinomycin
prior
directli
titer
timecours
observ
signific
chang
viral
titer
dose
figur
suggest
valinomycin
directli
inactiv
lacv
particl
final
confirm
phenotyp
measur
viral
rna
virus
expos
increas
dose
valinomycin
compar
rel
number
genom
titer
calcul
genometopfu
ratio
observ
number
chang
valinomycin
treatment
suggest
chang
specif
infect
figur
sum
data
suggest
valinomycin
affect
viru
infect
directli
act
virion
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
valinomycin
activ
alter
host
cell
activ
thu
hypothes
valinomycin
antivir
activ
due
effect
cell
role
potassium
bunyaviru
infect
welldocu
bunyaviru
entri
potassium
depend
test
valinomycin
affect
cell
rather
viru
treat
cell
valinomycin
immedi
infect
wash
away
drug
control
maintain
valinomycin
cell
replac
valinomycin
wash
away
initi
treatment
observ
even
remov
wash
valinomycin
cell
antivir
activ
persist
viral
titer
remain
reduc
level
valinomycin
treatment
concurr
infect
figur
togeth
data
suggest
valinomycin
directli
inactiv
viral
particl
treatment
cell
reduc
lacv
infect
potenti
disrupt
potassiumdepend
entri
ionophor
select
antivir
given
valinomycin
potassium
ionophor
wish
investig
whether
ionophor
potassium
otherwis
antivir
potassium
ion
play
crucial
role
cellular
entri
howev
role
sodium
calcium
ion
well
describ
marituba
viru
mtbv
infect
result
sodium
ion
influx
origin
function
ionic
chang
known
determin
ionophor
might
exhibit
antivir
activ
treat
cell
increas
dose
nonactin
potassium
sodium
ionophor
nigericin
hydrogen
potassium
ionophor
calcium
ionophor
sodium
ionophor
iii
figur
two
hour
later
infect
lacv
moi
measur
viral
titer
hpi
nonactin
nigericin
exhibit
signific
antivir
activ
viral
titer
measur
respect
figur
treatment
sodium
ionophor
iii
result
dosedepend
decreas
viral
titer
viru
recov
interestingli
treatment
calcium
ionophor
show
chang
viral
titer
even
highest
dose
thu
observ
lacv
replic
disrupt
sever
ionophor
especi
potassium
ionophor
highlight
role
potassium
viru
infect
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
research
directli
ad
lysat
collect
rna
purifi
accord
manufactur
protocol
util
directzol
rna
miniprep
plu
kit
zymo
research
purifi
rna
subsequ
use
cdna
synthesi
use
high
capac
cdna
revers
transcript
kit
thermofisch
accord
manufactur
protocol
ng
rna
random
hexam
primer
viral
genom
quantif
follow
cdna
synthesi
qrtpcr
perform
use
appli
biosystem
thermofisch
sybr
green
mastermix
dotscientif
sampl
held
min
prior
cycl
primer
verifi
linear
use
eightfold
serial
dilut
cdna
check
specif
via
melt
curv
analysi
follow
agaros
gel
electrophoresi
sampl
use
normal
total
rna
use
method
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
replenish
p
p
p
use
twotail
student
ttest
error
bar
repres
one
standard
error
mean
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
